Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Recurrence and survival rates in node negative patients after sentinel node biopsy for early-stage vulva cancer - A nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis

    Research output: Contribution to journalReviewResearchpeer-review

  3. The value of surgical staging in patients with apparent early stage epithelial ovarian carcinoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. HPV-prevalence in elderly women in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population

    Research output: Contribution to journalJournal articleResearchpeer-review

  • I Vergote
  • A du Bois
  • A Floquet
  • J Rau
  • J-W Kim
  • J M Del Campo
  • M Friedlander
  • S Pignata
  • K Fujiwara
  • N Colombo
  • M R Mirza
  • B J Monk
  • I Tsibulak
  • P M Calvert
  • T J Herzog
  • L C Hanker
  • J Meunier
  • J-Y Lee
  • A Bologna
  • M J Carrasco-Alfonso
  • P Harter
View graph of relations

OBJECTIVE: The AGO-OVAR16 study was designed to test the efficacy, safety, and tolerability of pazopanib maintenance after first-line chemotherapy in patients with newly diagnosed advanced ovarian cancer (AOC).

METHODS: Nine hundred and forty patients with histologically confirmed AOC, International Federation of Gynecology and Obstetrics (FIGO) stage II-IV, were randomized in a 1:1 ratio to receive either 800 mg pazopanib once daily or placebo for up to 24 months, unless there was disease progression, toxicity, withdrawal of consent, or death. The primary endpoint (investigator-assessed progression-free survival [PFS]) was met and previously reported. The results of final analyses of overall survival (OS) are reported here.

RESULTS: A third OS interim analysis showed futility and led to study closure and a final OS analysis after last patient last visit. At the time of the final OS analysis, 494 (89.7% of the planned 551) events had occurred. No difference was observed in OS between pazopanib and placebo. The hazard ratio (HR) was 0.960 (95% confidence interval [CI]: 0.805-1.145), and the median OS from randomization was 59.1 months in pazopanib and 64.0 months in placebo arms. For the East Asian patients, similar to the first three interim OS analyses, a numerical negative trend was observed favoring placebo (HR, 1.332; 95% CI: 0.863-2.054). Exploratory analyses showed a trend for a longer time to first subsequent anti-cancer therapy or death with pazopanib over placebo (HR, 0.829; 95% CI: 0.713-0.965), with a median estimate of 19.0 and 14.5 months, respectively. No new safety signals were observed.

CONCLUSION: Although pazopanib prolonged PFS, this was not associated with improvement in median OS.


Original languageEnglish
JournalGynecologic Oncology
Issue number2
Pages (from-to)186-191
Number of pages6
Publication statusPublished - Nov 2019

    Research areas

  • Adult, Aged, Angiogenesis Inhibitors/administration & dosage, Carcinoma, Ovarian Epithelial/drug therapy, Disease-Free Survival, Double-Blind Method, Drug Administration Schedule, Female, Humans, Middle Aged, Ovarian Neoplasms/drug therapy, Pyrimidines/administration & dosage, Quality of Life, Sulfonamides/administration & dosage, Treatment Outcome, Young Adult

ID: 59076616